background
paramyxovirus
includ
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
human
metapneumoviru
mpv
may
caus
signific
respiratori
tract
infecti
diseas
rtid
mortal
allogen
hematopoiet
cell
transplant
hct
howev
clinic
data
regard
frequenc
outcom
scarc
method
identifi
paramyxoviru
rtid
allogen
hct
recipi
diagnos
multiplex
polymeras
chain
reaction
baselin
characterist
patient
treatment
outcom
episod
analyz
ie
moder
sever
sever
immunodefici
verysid
accord
hct
month
tor
bcell
deplet
month
graftversushost
diseas
neutropenia
lymphopenia
hypogammaglobulinemia
result
one
hundr
three
rtid
episod
patient
identifi
piv
rsv
mpv
episod
occur
day
posthct
lower
rtid
account
thirtynin
percent
rtid
episod
requir
hospit
frequent
affect
patient
lower
rtid
six
percent
progress
upper
lower
rtid
overal
mortal
differ
paramyxovirus
sixtyon
percent
episod
occur
patient
sid
episod
occur
patient
verysid
oral
ribavirin
plu
intraven
immunoglobulin
administ
rtid
prefer
rsv
mpv
p
sid
patient
p
patient
verysid
frequent
progress
lower
rtid
p
requir
intens
care
unit
transfer
show
higher
mortal
conclus
paramyxoviru
rtid
remain
major
concern
allogen
hct
patient
fulfil
sid
verysid
emphas
efficaci
safe
antivir
treatment
urgent
need
high
risk
develop
lower
rtid
although
efficaci
rbvivig
formal
proven
clinic
experi
suggest
might
benefit
administ
earli
patient
presum
highest
risk
progress
lower
rtid
vitro
vivo
studi
demonstr
efficaci
rbv
ivig
piv
mpv
center
includ
consid
rbv
ivig
treatment
piv
mpv
rtid
allogen
hct
patient
clinic
paramet
suggest
sever
immunodefici
sid
despit
lack
support
studi
studi
investig
patient
characterist
manag
outcom
rtid
caus
paramyxovirus
allogen
hct
recipi
institut
singlecent
retrospect
studi
univers
hospit
basel
switzerland
allogen
hct
recipi
identifi
symptom
sign
rtid
detect
rsv
piv
mpv
multiplex
nucleic
acid
amplif
test
nat
nasopharyng
swab
np
bronchoalveolar
lavag
june
decemb
follow
pathogenspecif
quantit
realtim
nat
studi
approv
ethic
committe
nordwestand
zentralschweiz
upper
lower
rtid
defin
describ
recent
guidelin
upper
rtid
defin
viru
detect
upper
respiratori
secret
togeth
symptom
involv
upper
respiratori
tract
nose
throat
lower
rtid
defin
presenc
either
hypoxia
compat
pulmonari
infiltr
togeth
viru
detect
upper
lower
respiratori
secret
durat
viral
shed
defin
time
first
posit
first
neg
virolog
result
clearanc
document
neg
virolog
result
use
pathogenspecif
nat
multipl
episod
patient
consid
inclus
occur
least
week
apart
caus
differ
virus
viru
document
clinic
respons
clearanc
episod
indic
neg
nat
result
sever
immunodefici
defin
one
follow
allogen
hct
month
ago
acut
graftversushost
diseas
gvhd
grade
bronchiol
obliteran
leucopenia
liter
neutropenia
liter
lymphopenia
liter
hypogammaglobulinemia
gl
tcell
bcell
deplet
month
ago
verysid
defin
sid
criteria
contrast
moder
immunodefici
mid
defin
hct
month
ago
gvhd
grade
absolut
leucocyt
count
liter
absolut
lymphocyt
count
liter
absenc
immunosuppress
drug
treatment
mortal
attribut
viral
infect
defin
death
due
respiratori
failur
caus
identifi
except
lower
rtid
nasopharyng
swab
bronchoalveolar
lavag
bal
analyz
multiplex
nat
use
luminex
nxtag
respiratori
pathogen
panel
sensit
quantit
pathogenspecif
nat
appli
specif
followup
sampl
neg
forc
expiratori
volum
second
fev
vital
capac
express
percentag
predict
normal
valu
calcul
use
publish
equat
children
adult
infect
control
procedur
perform
previous
describ
treatment
decis
base
physician
discret
inform
institut
guidelin
recommend
either
system
rbv
ivig
system
rbv
plu
ivig
system
rbv
usual
administ
oral
load
dose
mgkg
bodyweight
follow
mg
threetim
daili
tid
thereaft
increas
mg
tid
day
mg
tid
day
intraven
immunoglobulin
administ
gkg
bodyweight
time
per
week
treatment
discontinu
clinic
respons
respiratori
virus
longer
detect
case
advers
event
eg
rbvinduc
hemolysi
patient
categor
accord
viru
type
degre
immunodefici
comparison
group
perform
analysi
varianc
pearson
test
fisher
exact
test
student
test
use
appropri
continu
categor
variabl
respect
univari
multivari
logist
regress
model
perform
determin
associ
need
hospit
p
valu
consid
signific
statist
analys
perform
stata
stata
corp
colleg
station
tx
june
decemb
paramyxoviru
rtid
episod
identifi
patient
caus
pathogen
piv
rsv
mpv
parainfluenza
viru
n
lead
agent
follow
n
n
n
tabl
show
baselin
characterist
paramyxoviru
episod
common
underli
diseas
acut
myeloid
leukemia
rtid
diagnosi
patient
complet
hematolog
remiss
patient
suffer
gvhd
grade
patient
baselin
characterist
differ
respect
viru
type
patient
episod
rtid
similar
baselin
characterist
supplementari
tabl
compar
patient
rtid
episod
nineteen
patient
suffer
differ
paramyxovirus
wherea
patient
infect
repeatedli
type
median
time
reoccurr
patient
infect
viru
day
rang
figur
rsv
mpv
infect
occur
frequent
winter
season
wherea
piv
infect
occur
commonli
autumn
compar
rsv
mpv
infect
p
importantli
frequenc
differ
paramyxoviru
infect
similar
spring
figur
moder
immunodefici
criteria
fulfil
episod
wherea
episod
occur
patient
sid
sid
group
episod
sid
criteria
therebi
fulfil
criteria
verysid
supplementari
tabl
upper
rti
identifi
patient
lower
rti
identifi
patient
includ
bal
diagnost
nat
tabl
moder
immunodefici
sid
patient
similar
rate
upper
lower
rtid
episod
lower
rtid
mid
patient
sid
patient
p
note
clinic
present
differ
differ
paramyxovirus
major
episod
present
without
fever
trend
elev
median
concentr
creactiv
protein
p
serumcreatinin
concentr
p
presenc
anemia
p
differ
viral
infect
group
data
shown
bacteri
coinfect
occur
episod
fungal
coinfect
seen
data
shown
viral
coinfect
seen
episod
includ
cytomegaloviru
rhinoviru
influenza
coronaviru
episod
adenoviru
respect
dual
paramyxoviru
infect
detect
piv
mpv
overal
paramyxoviru
rtid
treat
one
follow
treatment
regimen
ie
upper
rtidepisod
lower
rtidepisod
treatment
accord
viru
type
summar
tabl
oral
rbvivig
administ
episod
respiratori
syncyti
viru
mpv
episod
frequent
treat
rbvivig
piv
episod
p
intraven
immunoglobulin
alon
mainli
administ
piv
infect
compar
rsv
mpv
infect
group
respect
palivizumab
administ
patient
verysid
suffer
rsv
earli
posttranspl
period
episod
among
sid
patient
commonli
treat
episod
mid
patient
vs
p
episod
sid
patient
treat
rbvivig
includ
vs
mid
group
p
hemolysi
attribut
system
rbv
treatment
record
lead
drug
discontinu
sequenti
viral
sampl
perform
episod
median
durat
viral
shed
differ
within
viral
rtid
group
p
tabl
similar
mid
sid
patient
iqr
day
iqr
respect
p
six
episod
progress
upper
lower
rtid
five
episod
progress
lower
rtid
belong
sid
group
treat
rbvivig
phase
upper
rtid
one
episod
piv
infect
mid
patient
progress
lower
rtid
without
administr
antivir
drug
progress
lower
rtid
differ
patient
mid
sid
p
contrast
episod
verysid
patient
tend
higher
progress
rate
p
compar
patient
mid
sid
taken
togeth
pulmonari
function
test
pft
perform
episod
episod
sequenti
pft
avail
overal
reduct
fev
baselin
pft
rtid
diagnosi
document
rtid
caus
rsv
piv
pft
month
resolut
rtid
show
compar
tabl
dlcocva
measur
episod
margin
influenc
rtid
data
shown
respect
patient
previou
diagnosi
bronchiol
obliteran
pft
remain
stabl
resolut
rtid
forti
rtid
episod
requir
hospit
lower
rtid
absenc
hematolog
complet
remiss
hct
month
well
presenc
verysid
criteria
p
significantli
associ
higher
risk
hospit
univari
analysi
tabl
multivari
analysi
presenc
lower
rtid
verysid
remain
signific
predictor
hospit
six
episod
admit
intens
care
unit
requir
mechan
ventil
tabl
episod
patient
verysid
commonli
requir
intens
care
tabl
overal
mortal
rtid
episod
death
occur
patient
verysid
tabl
respiratori
tract
infecti
diseaseattribut
mortal
occur
episod
caus
mpv
rsv
tabl
studi
investig
episod
paramyxoviru
rtid
identifi
multiplex
nat
current
era
allogen
hct
unlik
previou
studi
report
followup
first
day
posttranspl
paramyxoviru
rtid
occur
day
posttranspl
median
time
close
year
notabl
lower
rtid
account
episod
patient
requir
admiss
thu
paramyxoviru
rtid
allogen
hct
continu
pose
signific
clinic
burden
overal
mortal
low
inde
lower
compar
previou
report
typic
occur
verysid
patient
sid
criteria
thu
patient
suscept
appear
key
determin
outcom
even
year
allogen
hct
point
immunolog
still
vulner
time
period
reason
later
present
paramyxoviru
rtid
compar
report
present
unknown
howev
may
reflect
differ
studi
design
earlier
studi
limit
day
posttranspl
well
chang
manag
communityacquir
respiratori
viru
infect
deferr
hct
consist
use
multiplex
nat
symptomat
patient
includ
outpati
close
followup
overal
longer
surviv
hct
recent
studi
also
demonstr
rtid
continu
occur
high
frequenc
late
posthct
phase
median
month
given
patient
part
hematolog
remiss
return
normal
less
protect
life
social
contact
appear
plausibl
explain
exposur
respiratori
virus
within
first
year
allogen
hct
thu
awar
extend
time
vulner
emerg
studi
well
other
may
import
observ
futur
antivir
vaccin
develop
also
reflect
recent
complet
trial
rsv
fusion
inhibitor
presatovir
patient
present
upper
lower
rtid
day
month
day
month
posttransplant
rtid
episod
center
manag
without
hospit
patient
uncompl
cours
low
progress
rate
lower
rtid
absenc
persist
airflow
obstruct
low
mortal
may
explain
better
gener
clinic
condit
partial
immun
reconstitut
expect
later
posthct
reflect
lower
number
patient
neutropenia
lymphopenia
recent
studi
kim
et
al
identifi
absolut
lymphocyt
count
liter
time
upper
rtid
onset
protect
regard
progress
lower
rtid
agreement
data
illustr
patient
upper
rtid
absolut
lymphocyt
count
liter
progress
lower
rtid
contrast
threshold
liter
report
risk
factor
progress
adopt
earlier
studi
wherea
other
propos
close
relat
cutoff
liter
thu
low
low
lymphocyt
count
import
determin
progress
outcom
impact
treatment
rbv
andor
ivig
outcom
ascertain
studi
due
lack
appropri
size
prefer
random
control
group
howev
abbrevi
allohct
allogen
hematopoet
cell
transplant
ci
confid
interv
hla
human
leucocyt
antigen
odd
ratio
rsv
respiratori
syncyti
viru
rtid
respiratori
tract
infecti
diseas
sid
sever
immunodefici
model
includ
follow
lower
rtid
allohct
month
hematolog
complet
remiss
correct
episod
among
equal
patient
hosmerlemeshow
p
b
sid
criteria
defin
allohct
month
ago
graftversushostdiseas
grade
leucopenia
liter
neutropenia
liter
lymphopenia
liter
hypogammaglobulinemia
gliter
tcell
bcell
deplet
month
ago
studi
difficult
conduct
given
ethic
concern
oper
protocol
also
reflect
recent
studi
presatovir
system
rbv
exclud
rather
patient
stratifi
accord
use
first
report
system
rbv
ivig
consist
avail
discret
treat
physician
center
togeth
intern
guidanc
regard
administr
support
data
exist
rsvrtid
accordingli
paramyxoviru
rtid
episod
treat
rbvivig
mainli
administ
rsvand
mpvrtid
wherea
ivig
alon
prefer
piv
rtid
studi
use
rbv
associ
hemolysi
lead
discontinu
drug
typic
day
therapi
overal
found
low
complic
rate
paramyxovirus
regard
number
import
paramet
progress
upper
lower
rtid
need
hospit
fix
airflow
obstruct
rtid
resolut
well
overal
virusattribut
mortal
thu
question
aris
whether
sid
verysid
patient
particular
would
fare
wors
without
treatment
recent
metaanalysi
demonstr
efficaci
aerosol
system
rbv
without
immunomodul
rsv
infect
patient
allogen
hct
contrast
impact
system
rbv
mpvand
pivrtid
undefin
studi
treatment
often
provid
set
mpv
infect
piv
infect
although
observ
differ
progress
lower
rtid
mortal
seem
viral
shed
shorter
rbvtreat
mpv
infect
trend
found
piv
view
unmet
clinic
need
paramyxoviru
rtid
hct
undocu
efficaci
follow
key
question
remain
treat
paramyxoviru
rtid
treat
rbvivig
better
specif
potent
antivir
therapi
becom
avail
conclud
studi
sid
patient
particularli
verysid
patient
fulfil
sid
criteria
treat
safe
system
rbvivig
wherea
ivig
alon
offer
patient
pivrtid
shah
et
al
recent
identifi
risk
factor
poor
outcom
rsvrtid
allogen
hct
propos
score
index
classifi
patient
low
score
moder
score
high
risk
progress
identifi
would
benefit
inhal
rbvbase
antivir
therapi
propos
criteria
similar
also
introduc
age
year
myeloabl
condit
regimen
use
corticosteroid
within
prior
day
center
previous
report
criteria
report
time
ago
avail
use
sinc
seen
direct
comparison
substanti
overlap
supplementari
tabl
unfortun
score
shah
et
al
await
independ
valid
valid
prospect
set
done
appli
simpler
criteria
sid
respiratori
viru
rtid
essenti
similar
conclus
taken
togeth
data
support
view
host
immunodefici
remain
major
determin
outcom
rsv
also
mpv
piv
thu
need
valid
risk
strata
prospect
trial
balanc
treatment
versu
overtreat
advers
event
particularli
mid
hct
patient
studi
sever
limit
first
use
comprehens
specif
sensit
diagnost
test
multiplex
nat
facilit
diagnosi
initi
time
treatment
screen
advoc
center
larg
restrict
diagnosi
symptomat
patient
potenti
late
present
treatment
may
readili
modifi
outcom
shown
influenza
second
although
standard
guidelin
therapeut
regimen
infect
hospit
use
base
discret
treat
physician
thu
sever
present
may
favor
treatment
third
studi
lack
random
control
group
evalu
treatment
approach
prospect
conduct
trial
rbv
await
result
current
ongo
trial
test
specif
design
new
antivir
rsv
hope
paramyxovirus
final
although
includ
larg
cohort
hematolog
patient
singlecent
studi
therefor
result
might
transfer
center
conclus
report
paramyxoviru
rtid
frequent
day
allogen
hct
clinic
sever
sid
patient
despit
preferenti
antivir
treatment
although
definit
conclus
efficaci
made
current
mortal
reduc
compar
earlier
studi
data
suggest
time
diagnosi
earli
treatment
effect
panparamyxoviru
antivir
major
impact
morbid
mortal
sid
hct
patient
well
design
random
studi
need
valid
risk
strata
balanc
treatment
versu
overtreat
advers
event
supplementari
materi
avail
open
forum
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
